Study of a New Anticoagulant Drug in Patients With Atrial Fibrillation

Completed · Phase 2

Conditions studied: Atrial Fibrillation

In brief

The primary purpose of this study (CLN-504) is to determine the safety and develop a dosing regimen of an investigational anticoagulant drug (ATI-5923) in patients with atrial fibrillation.

Key facts

Study ID

NCT00431782

Run by

ARYx Therapeutics

People needed

60

Starts

2006-12-01

Expected to finish

2007-10-01

Last updated by the study team

2007-11-08

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Documented atrial fibrillation
• Candidate for anticoagulation or currently receiving warfarin at screening
• Males or females greater than 18 years of age
• Males or females with a CHADS2 score of 0 to 2

You may not qualify if…

• Contraindications to anticoagulation e.g., active bleeding
• Taking other anticoagulant or antiplatelet agents other than low-dose aspirin
• History of myocardial infarction, acute coronary syndrome, or coronary revascularization procedure within the past 3 months prior to Day 1
• History of laboratory values suggestive of anemia (i.e., Hb <10 gm/dL)
• Women of childbearing potential

Where it is running

• ARYx Investigational Site — Anaheim, California, United States
• ARYx Investigational Site — Yuba City, California, United States
• ARYx Investigational Site — Deerfield Beach, Florida, United States
• ARYx Investigational Site — Winfield, Illinois, United States
• ARYx Investigational Site — Oklahoma City, Oklahoma, United States
• ARYx Investigational Site — Wellsboro, Pennsylvania, United States
• ARYx Investigational Site — Wynnewood, Pennsylvania, United States
• ARYx Investigational Site — Greer, South Carolina, United States
• ARYx Investigational Site — Spartanburg, South Carolina, United States
• ARYx Investigational Site — Memphis, Tennessee, United States
• ARYx Investigational Site — San Antonio, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.